Lynda Charters

home / authors / lynda-charters

Lynda Charters Enoch started her early “eye life” at the Schepens Eye Research Institute, Boston, which ultimately culminated in her current position as an Editor of Ophthalmology Times.

Articles

anti-VEGF after radiation therapy

Anti-VEGF therapy may prevent/delay radiation maculopathy in choroidal melanoma

Lynda Charters
July 13th 2020

Immediate administration after radiation therapy is key.

Read More

subretinal gene therapy

Subretinal gene therapy safe with visual benefit

Lynda Charters
June 18th 2020

This study provided clinical proof of concept for viral vector-mediated gene supplementation therapy of inherited day blindness caused by pathogenic variants in the cone photoreceptor-specific gene CNGA3.

Read More

Real world versus patient trials

How DME patients may fare differently in ‘real world’ versus trials

Lynda Charters
May 4th 2020

Read More

artificial intelligence

Screening DR + tele-ophthalmology AI: Less expensive than human assessment

Lynda Charters
May 4th 2020

Read More

chronic intravitreal injections

Determining risk of ocular damage from chronic intravitreal injections

Lynda Charters
April 24th 2020

Read More

Collagen corneal CXL

PACK-CXL researchers continue to clear hurdles of topical drugs

Lynda Charters
April 16th 2020

Read More

Pediatric eye patient

Technology 'perfect' for pediatric neuro-ophthalmology diagnoses

Lynda Charters
April 13th 2020

Read More

Coronavirus

Researchers find low risk of COVID-19 transmission in tears

Lynda Charters
April 11th 2020

Read More

What retinal specialists should know about their pregnant patients

What retinal specialists should know about their pregnant patients

Lynda Charters
April 1st 2020

Read More

How autonomous diagnostics for DR gave a ‘jump-start’ to AI in ophthalmology

How autonomous diagnostics for DR gave a ‘jump-start’ to AI in ophthalmology

Lynda Charters
March 30th 2020

Read More

AMD awareness: Close focus on preserving vision

AMD awareness: Close focus on preserving vision

Lynda Charters
February 21st 2020

Read More

Stem cell therapy

Stem cell transplantation: Restoring vision in AMD may be possible

Lynda Charters
February 10th 2020

Read More

Connect the dots: Diagnosing, managing multifocal choroiditides

Connect the dots: Diagnosing, managing multifocal choroiditides

Lynda Charters
January 31st 2020

Read More

retina risk app

Retina risk app tool empowers diabetic patients worldwide

Lynda Charters
August 1st 2019

Read More

diabetic retinopathy

Obesity + diabetic retinopathy: Korean study explores inverse association

Lynda Charters
July 16th 2019

Read More

diabetic retinopathy genetics

DNA analysis: Unraveling role of genetics in DR pathogenesis

Lynda Charters
July 16th 2019

Read More

Diabetic retinopathy

Lipid-lowering drugs, lower DR risk may go hand in hand

Lynda Charters
July 1st 2019

Read More

Laser treatment for DME: Still a place at the table

Laser treatment for DME: Still a place at the table

Lynda Charters
June 3rd 2019

Read More

Determining DR progression: Much work still needs to be done

Determining DR progression: Much work still needs to be done

Lynda Charters
May 21st 2019

Read More

Image-reading accuracy Increases with deep-learning DR algorithms

Image-reading accuracy Increases with deep-learning DR algorithms

Lynda Charters
May 14th 2019

Read More

Laser’s place in diabetic retinopathy: Choosing the right scenario

Laser’s place in diabetic retinopathy: Choosing the right scenario

Lynda Charters
April 1st 2019

Read More

Successful PDR outcomes driven by strict adherence to follow-up

Successful PDR outcomes driven by strict adherence to follow-up

Lynda Charters
April 1st 2019

Read More

Adalimumab efficacious for uveitis regardless of disease duration

Adalimumab efficacious for uveitis regardless of disease duration

Lynda Charters
March 7th 2019

Quiescence, steroid-free quiescence achieved in VISUAL III trial

Read More

Managing uveitic macular edema

Managing uveitic macular edema

Lynda Charters
March 6th 2019

Intravitreal triamcinolone acetonide, dexamethasone implant superior for regional treatment of disorder

Read More

Cataract surgery in patients with diabetes: No time like the present

Cataract surgery in patients with diabetes: No time like the present

Lynda Charters
March 1st 2019

Read More

Optical coherence tomography (OCT)

When and how to treat myopic traction maculopathy

Lynda Charters
July 3rd 2018

Read More

New name for an old problem

New name for an old problem

Lynda Charters
June 8th 2018

Read More

Steroid therapy for DME: Yes or maybe?

Steroid therapy for DME: Yes or maybe?

Lynda Charters
June 1st 2018

Read More

Site Logo

Suprachoroidal space: Promising route for retinal drug delivery

Lynda Charters
May 4th 2018

Read More

Site Logo

Making strides in uveitis therapy

Lynda Charters;Thomas A. Albini, MD
April 30th 2018

Read More

<1
...
181920212223>

Latest Updated Articles

RWC 2025: Companies to share data at meeting in Fort Lauderdale
Published: April 17th 2025 | Updated: May 1st 2025
RWC 2025: Companies to share data at meeting in Fort Lauderdale
Successful phase 1B study of oral therapy for diabetic retinopathy
Published: June 25th 2025 | Updated: July 3rd 2025
Successful phase 1B study of oral therapy for diabetic retinopathy
Brazil’s ANVISA grants marketing authorization to Lucentis biosimilar FYB201 (Ranivisio, Formycon/Bioeq AG)
Published: June 8th 2025 | Updated: July 3rd 2025
Brazil’s ANVISA grants marketing authorization to Lucentis biosimilar FYB201 (Ranivisio, Formycon/Bioeq AG)
1 expert is featured in this series.
Published: June 3rd 2025 | Updated: July 3rd 2025
Rapid Improvements In DME With Next-Generation Anti-VEGF Therapies: Case Highlights
1 expert in this video
Published: June 3rd 2025 | Updated: July 3rd 2025
Improved Retinal Drying and Treatment Durability In nAMD With Aflibercept 8 mg
Ocugen signs term sheet for Korean licensing of OCU400 gene therapy
Published: June 9th 2025 | Updated: July 3rd 2025
Ocugen signs term sheet for Korean licensing of OCU400 gene therapy
© 2025 MJH Life Sciences

All rights reserved.